Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Foresee offloads clinical-stage MMP-12 inhibitors in $584M deal
Foresee has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate cancer med Camcevi.
James Waldron
Jan 8, 2026 7:45am
Amgen dances with Disco in $618M cancer target pact
Jan 7, 2026 10:15am
Basilea pens collab with US biotech to develop antifungal
Jan 7, 2026 7:05am
Boehringer continues kidney dealmaking with $120M Variant pact
Jan 6, 2026 10:45am
Roche commits $100M to keep its GLP-1 Structure sound
Jan 6, 2026 10:21am
Lilly returns to Nimbus in $1.3B deal to create oral obesity med
Jan 6, 2026 10:05am
